Kodiak Sciences (KOD) Corporate presentation summary

Strategic pipeline and clinical progress

• Advancing three Phase 3 retina programs with topline data readouts expected in 2026–2027, targeting wet AMD, diabetic retinopathy, retinal vein occlusion, and MESI.

• Tarcocimab and KSI-501 leverage the ABC® platform for high immediacy and industry-leading durability, with BLA filings planned for 2026–2027.

• KSI-101, a dual IL-6/VEGF inhibitor, demonstrated robust Phase 1b APEX results in MESI, with pivotal PEAK and PINNACLE studies underway.

• Commercial opportunity exceeds 150,000 initial addressable MESI patients in the US, with significant headroom for growth.

• Proprietary, wholly owned assets provide flexibility in commercialization and risk diversification.

Market landscape and unmet needs

• The $15+ billion anti-VEGF market remains open for therapies combining high immediacy and durability, as current biologics fall short in real-world durability.

• Existing treatments for MESI, primarily steroids, carry significant safety risks and limited efficacy, highlighting a need for safer, potent, locally administered therapies.

• KSI-101 targets a population often contraindicated for steroids or refractory to current treatments, aiming to simplify the patient journey and improve outcomes.

• Most MESI patients are managed by general ophthalmologists and retinal specialists, with complex cases referred to uveitis specialists.

Technology and manufacturing

• The ABC® platform enables modular, multi-functional therapies with tailored drug release, supporting both ophthalmic and systemic indications.

• Tarcocimab and KSI-501 combine unconjugated and conjugated proteins for rapid disease control and extended dosing intervals.

• Commercial-scale manufacturing facility (Ursus) is operational, supporting large-scale production and BLA-facing validation batches.